-- 山东新华药业（港交所代码：0719，沪交所代码：000756）周三在香港联交所提交的公告显示，其布美他尼注射液的药品注册申请已获中国国家药品监督管理局批准。 公告称，该药适用于治疗心脏、肝脏和肾脏疾病引起的水肿，以及高血压和急性肾功能衰竭等疾病。
Related Articles
Asia
Changhong's Attributable Profit Plummets 72% in Q1
Sichuan Changhong Electric's (SHA:600839) attributable profit fell 72% to 98.5 million yuan in the first quarter from 345.5 million yuan in the year-ago period, according to a Saturday filing with the Shanghai bourse.Earnings per share at the consumer electronics manufacturer decreased 71% to 0.0214 yuan from 0.0748 yuan in the prior-year period.Operating income edged up 1.6% year over year to 27.3 billion yuan from 26.8 billion yuan.Shares decreased 5% during morning trading on Monday.
$SHA:600839
Asia
China Energy Engineering Logs 29% Decrease in Q1 2026 Contract Value
China Energy Engineering (SHA:601868, HKG:3996) logged a 29% year-on-year decrease in total new contract value in the first quarter of 2026, according to a Hong Kong bourse filing Friday.Hong Kong-listed shares of the construction firm fell over 2% in Monday late morning trade.The value of new contracts reached 276.2 billion yuan during the quarter, including 184.81 billion yuan from domestic sources and 91.39 billion yuan from overseas.
$HKG:3996$SHA:601868
Asia
Shanghai Zhangjiang Hi-Tech Park Development's Attributable Profit Slides 72% in Q1; Shares Fall 3%
Shanghai Zhangjiang Hi-Tech Park Development's (SHA:600895) attributable profit fell 72% to 83.5 million yuan in the first quarter from 294.5 million yuan in the year-ago period, according to a Saturday filing with the Shanghai bourse.Earnings per share at the real estate developer decreased 72% to 0.05 yuan from 0.18 yuan in the prior-year period.Operating income declined 31% year over year to 838 million yuan from 1.22 biliion yuan.Shares decreased 3% during the midday trade on Monday.
$SHA:600895